search
Back to results

Rheumatologists and the Requesting of Antinuclear Antibodies (ANA) Tests in Patients With Rheumatologic Complaints

Primary Purpose

Rheumatic Diseases

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Education and feedback
Sponsored by
Sint Maartenskliniek
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Rheumatic Diseases focused on measuring Antinuclear antibody (ANA), Overuse, Rheumatologists, Quality of care

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria rheumatologists:

  • rheumatologists who are consulting patients at the rheumatology outpatient clinic of a participating centre

Exclusion Criteria rheumatologists:

  • rheumatologists not working the full study period (pre- and post-intervention) at a participating centre
  • rheumatologists not giving their consent to participate

Inclusion Criteria patients - all patients with an ANA test requested by an included rheumatologist during the study period

Exclusion Criteria patients

- patients with an ANA test requested during a clinical admission

Sites / Locations

  • Sint Maartenskliniek
  • Radboud University Medical Center
  • Maartenskliniek Woerden

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Education and feedback

Arm Description

The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.

Outcomes

Primary Outcome Measures

Change from baseline (pre-intervention) ANA/new patient ratio (APR) at 12 months (post-intervention)
Number of ANA tests divided by the number of new patients
Change from baseline (pre-intervention) % of positive ANA tests at 12 months (post-intervention)
Percentage of ANA tests reported as positive by the local laboratory. ANA tests reported as 'weakly positive' are regarded as negative.
Change from baseline (pre-intervention) % of repeated ANA testing at 12 months (post-intervention)
Percentage of patients with ≥1 ANA test in 12 months (pre- or post-intervention period)
Change from baseline (pre-intervention) % of ANA associated diagnoses at 12 months (post-intervention)
Percentage of patients, in which an ANA is done during the study period, with final diagnosis of SLE, SSc, PM/DM, MCTD or SS
Change from baseline (pre-intervention) APR variation between rheumatologists at 12 months (post-intervention)
Standard deviation around the mean APR, calculated from the APRs of the individual rheumatologists
Change from baseline (pre-intervention) reaching the of target APR at 12 months (post-intervention)
Difference (percentage) between the actual APR and the target-APR defined during the intervention

Secondary Outcome Measures

Full Information

First Posted
March 9, 2015
Last Updated
March 31, 2015
Sponsor
Sint Maartenskliniek
search

1. Study Identification

Unique Protocol Identification Number
NCT02409251
Brief Title
Rheumatologists and the Requesting of Antinuclear Antibodies (ANA) Tests in Patients With Rheumatologic Complaints
Official Title
Requesting Behaviour of Rheumatologists Regarding Antinuclear Antibodies (ANA) in Patients With Rheumatologic Complaints
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
July 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sint Maartenskliniek

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to assess the effect of a simple intervention (a combination of education and feedback) on Antinuclear Antibody (ANA) testing. This aim was chosen because of the known overuse of many laboratory tests, of which ANA testing is one. As overuse of ANA tests can have negative consequences (both for patients and society), the investigators designed an intervention to see how this would influence Antinuclear Antibody testing by rheumatologists.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatic Diseases
Keywords
Antinuclear antibody (ANA), Overuse, Rheumatologists, Quality of care

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
29 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Education and feedback
Arm Type
Experimental
Arm Description
The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
Intervention Type
Behavioral
Intervention Name(s)
Education and feedback
Primary Outcome Measure Information:
Title
Change from baseline (pre-intervention) ANA/new patient ratio (APR) at 12 months (post-intervention)
Description
Number of ANA tests divided by the number of new patients
Time Frame
Pre- and post-intervention (both 12 months)
Title
Change from baseline (pre-intervention) % of positive ANA tests at 12 months (post-intervention)
Description
Percentage of ANA tests reported as positive by the local laboratory. ANA tests reported as 'weakly positive' are regarded as negative.
Time Frame
Pre- and post-intervention (both 12 months)
Title
Change from baseline (pre-intervention) % of repeated ANA testing at 12 months (post-intervention)
Description
Percentage of patients with ≥1 ANA test in 12 months (pre- or post-intervention period)
Time Frame
Pre- and post-intervention (both 12 months)
Title
Change from baseline (pre-intervention) % of ANA associated diagnoses at 12 months (post-intervention)
Description
Percentage of patients, in which an ANA is done during the study period, with final diagnosis of SLE, SSc, PM/DM, MCTD or SS
Time Frame
Pre- and post-intervention (both 12 months)
Title
Change from baseline (pre-intervention) APR variation between rheumatologists at 12 months (post-intervention)
Description
Standard deviation around the mean APR, calculated from the APRs of the individual rheumatologists
Time Frame
Pre- and post-intervention (both 12 months)
Title
Change from baseline (pre-intervention) reaching the of target APR at 12 months (post-intervention)
Description
Difference (percentage) between the actual APR and the target-APR defined during the intervention
Time Frame
Pre- and post-intervention (both 12 months)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria rheumatologists: rheumatologists who are consulting patients at the rheumatology outpatient clinic of a participating centre Exclusion Criteria rheumatologists: rheumatologists not working the full study period (pre- and post-intervention) at a participating centre rheumatologists not giving their consent to participate Inclusion Criteria patients - all patients with an ANA test requested by an included rheumatologist during the study period Exclusion Criteria patients - patients with an ANA test requested during a clinical admission
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronald van Vollenhoven, MD, PhD
Organizational Affiliation
Karolinska Institutet
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marlies Hulscher, PhD
Organizational Affiliation
Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, the Netherlands
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alfons den Broeder, MD, PhD
Organizational Affiliation
Sint Maartenskliniek, Nijmegen, the Netherlands
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sint Maartenskliniek
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500 GM
Country
Netherlands
Facility Name
Radboud University Medical Center
City
Nijmegen
Country
Netherlands
Facility Name
Maartenskliniek Woerden
City
Woerden
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
26414008
Citation
Lesuis N, Hulscher ME, Piek E, Demirel H, van der Laan-Baalbergen N, Meek I, van Vollenhoven RF, den Broeder AA. Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists. Arthritis Care Res (Hoboken). 2016 Apr;68(4):562-9. doi: 10.1002/acr.22725.
Results Reference
derived

Learn more about this trial

Rheumatologists and the Requesting of Antinuclear Antibodies (ANA) Tests in Patients With Rheumatologic Complaints

We'll reach out to this number within 24 hrs